CtDNA After Chemotherapy in Elderly Patients With Acute Leukemia

Navy General Hospital, Beijing200 enrolled

Overview

This study will monitor CtDNA After Chemotherapy in Elderly Patients With AL

This study will use droplet digital PCR (ddPCR) method to quantify peripheral blood plasma mutant allele frequency (MAF) in elderly acute leukemia patients after chemotherapy to evaluate the clinical value of CtDNA .

Study Type

OBSERVATIONAL

Enrollment

200

Conditions

Acute Leukemia

Eligibility

Sex: ALLMin age: 60 YearsMax age: 100 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Written informed consent * Male * not pregnant female * patients \>=60 years old * Diagnosis of acute leukemia Exclusion Criteria: * Pregnancy * HIV positive * patients \>=100 years old

Locations (1)

Navy General Hospital

Beijing, China

RECRUITING

Outcomes

Primary Outcomes

cumulative incidence of relapse(CIR)

cumulative incidence of relapse

Time frame: through study completion, an average of 1 year

Secondary Outcomes

overall survival (OS)

overall survival

Time frame: through study completion, an average of 2 years

Central Contacts

Liren Qian, MD

CONTACT

+861066957676 qlr2007@126.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.